henry meds oral semaglutide GLP-1 Review 2026: Great Care With Trade-Offs LifeMD vs. Henry Meds: Weight

Take The Quiz Mohit Joshipura Chief Medical Officer BA, Texas Tech University Alex Pandajis Medical Director PhD, Quinnipiac University Jordan Cobb Clinical Education Director MA, Vanderbilt University Jessica Schoening Team Lead MSc, Texas State University Kevin Lundell Clinician MSc, Thomas Jefferson University GLP-1 meds are in demand from major suppliers

Retatrutide is an investigational peptide drug developed by Eli Lilly that acts as a triple agonist, simultaneously targeting three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors

For most people, any gastrointestinal side effects experienced on day one will begin to settle within 48 to 72 hours

Provider-Guided Decision Framework for New Mothers Deciding whether to continue or start semaglutide during breastfeeding involves weighing maternal metabolic health against theoretical infant exposure

If these problems persist, then you should reach out to your provider